Patents Assigned to Precision Therapeutics, Inc.
-
Publication number: 20100216168Abstract: The present invention provides a method of evaluating the angiogenic potential of a tumor, and for predicting the efficacy of anti-angiogenic therapies on an individualized basis. The method of the invention involves preparing an angiogenic signature for malignant cells in culture by assaying for the presence or level of one or more angiogenesis-related factors selected from VEGF/VPF, IL8/CXCL8, TGF-?1, TGF-?2, TGF-?3, bFGF/FGF-2, EGF, PDGF-AA, PDGF-AA/BB, IP-10, and Flt-3 ligand. The angiogenic signature may be prepared from cultures maintained under normoxic and/or hypoxic environments. The invention may be used in conjunction with chemoresponse testing of anti-tumor agents, to predict or suggest a combination therapy for cancer patients.Type: ApplicationFiled: March 24, 2008Publication date: August 26, 2010Applicant: PRECISION THERAPEUTICS, INC.Inventors: Jamie Heinzman, Stacey Brower, Jason Bush, Zhibao Mi
-
Patent number: 7771963Abstract: An improved system for screening a multiple of candidate therapeutic or chemotherapeutic agents for efficacy as to a specific patient, in which a tissue sample from the patient is harvested, cultured and separately exposed to a plurality of treatments and/or therapeutic agents for the purpose of objectively identifying the best treatment or agent for the particular patient. Specific method innovations such as tissue sample preparation techniques render this method practically as well as theoretically useful. By subjecting uniform samples of cells to a wide variety of active agents (and concentrations thereof), the most promising agent and concentration for treatment of a particular patient can be determined.Type: GrantFiled: October 2, 2008Date of Patent: August 10, 2010Assignee: Precision Therapeutics, Inc.Inventor: Paul L. Kornblith
-
Publication number: 20100143948Abstract: The assays, methods, tools and systems discussed herein represent an improved and unified system for monitoring the progression of an individual patient malignancy. The assays, methods, tools and systems discussed herein represent an improved and unified system for monitoring and for identifying cellular and secreted markers, for screening cells to detect phenotypic and genotypic drift and for predicting chemotherapeutic response of patient tumor cells to at least one therapeutic agent. The assays, methods, tools and systems discussed herein also represent an improved and unified system for monitoring and for screening multiple pharmaceutical agents for efficacy and long term effect as to a specific patient.Type: ApplicationFiled: November 19, 2009Publication date: June 10, 2010Applicant: Precision Therapeutics Inc.Inventors: Michael Gabrin, Stacey Brower, Sean McDonald, Holly Gallion, Payal Nanavati, Shara Dawn Rice, Anuja Chattopadhyay
-
Patent number: 7678552Abstract: An improved system for screening a multiple of candidate therapeutic or chemotherapeutic agents for efficacy as to a specific patient, in which a tissue sample from the patient is harvested, cultured and separately exposed to a plurality of treatments and/or therapeutic agents for the purpose of objectively identifying. One particularly important tissue sample preparation technique is the initial preparation of cohesive multicellular particulates of the tissue sample. For assays concerning cancer treatment, a two-stage evaluation is contemplated in which both acute cytotoxic and longer term inhibitory effect of a given anti-cancer agent are investigated.Type: GrantFiled: September 10, 2008Date of Patent: March 16, 2010Assignee: Precision Therapeutics, Inc.Inventor: Paul L. Kornblith
-
Patent number: 7642048Abstract: The assays, methods, tools and systems discussed herein represent an improved and unified system for monitoring the progression of an individual patient malignancy. The assays, methods, tools and systems discussed herein represent an improved and unified system for monitoring and for identifying cellular and secreted markers, for screening cells to detect phenotypic and genotypic drift and for predicting chemotherapeutic response of patient tumor cells to at least one therapeutic agent. The assays, methods, tools and systems discussed herein also represent an improved and unified system for monitoring and for screening multiple pharmaceutical agents for efficacy and long term effect as to a specific patient.Type: GrantFiled: April 23, 2007Date of Patent: January 5, 2010Assignee: Precision Therapeutics Inc.Inventors: Michael Gabrin, Stacey Brower, Sean McDonald, Holly Gallion, Payal Nanavati, Shara Dawn Rice, Anuja Chattopadhyay
-
Patent number: 7575868Abstract: Methods are provided for accurately predicting efficacy of chemotherapeutic agents. Methods of the invention increase the positive predictive value of chemosensitivity assays by assessing both the ability of a chemotherapeutic to destroy cells and the genetic propensity of those cells for resistance. Results obtained using methods of the invention provide insight into the in vivo effectiveness of a therapeutic, and lead to more effective chemotherapeutic treatment.Type: GrantFiled: March 5, 2007Date of Patent: August 18, 2009Assignee: Precision Therapeutics, Inc.Inventors: Paul L. Kornblith, Sean McDonald
-
Patent number: 7563593Abstract: The present invention provides an improved system for determining factors secreted from patient cells, in which a tissue sample from the patient is harvested and cultured. One particularly important tissue sample preparation technique is the initial preparation of cohesive multicellular particulates of the tissue sample. The tissue sample technique of the present invention is also-useful in assaying expression and/or secretion of various markers, factors or antigens present on or produced by the cultured cells for diagnostic purposes and for using such expression to monitor the applicability of certain candidate therapeutic or chemotherapeutic agents and the progress of treatment with those agents.Type: GrantFiled: August 15, 2006Date of Patent: July 21, 2009Assignee: Precision Therapeutics, Inc.Inventor: Paul L. Kornblith
-
Patent number: 7501260Abstract: An improved system for screening a multiple of candidate therapeutic or chemotherapeutic agents for efficacy as to a specific patient, in which a tissue sample from the patient is harvested, cultured and separately exposed to a plurality of treatments and/or therapeutic agents for the purpose of objectively identifying the best treatment or agent for the particular patient. Specific method innovations such as tissue sample preparation techniques render this method practically as well as theoretically useful. One particularly important tissue sample preparation technique is the initial preparation of cohesive multicellular particulates of the tissue sample, rather than enzymatically dissociated cell suspensions or preparations, for initial tissue culture monolayer preparation.Type: GrantFiled: November 26, 2007Date of Patent: March 10, 2009Assignee: Precision Therapeutics, Inc.Inventor: Paul L. Kornblith
-
Patent number: 7314731Abstract: The present invention discloses in vitro methods for screening candidate therapeutic and/or chemotherapeutic agents for in vivo efficacy in a specific patient. The invention also includes methods for determining the optimal dosage of a therapeutic agent for a specific patient. The methods include the use of cohesive multicellular particulates of tissue, rather than enzymatically dissociated cell suspensions or preparations, to prepare tissue culture monolayers representative of in vivo cell populations.Type: GrantFiled: March 17, 2005Date of Patent: January 1, 2008Assignee: Precision Therapeutics, Inc.Inventor: Paul L. Kornblith
-
Patent number: 7112415Abstract: An improved system for screening a multiple of candidate therapeutic or chemotherapeutic agents for efficacy as to a specific patient, in which a tissue sample from the patient is harvested, cultured and separately exposed to a plurality of treatments and/or therapeutic agents for the purpose of objectively identifying. One particularly important tissue sample preparation technique is the initial preparation of cohesive multicellular particulates of the tissue sample. For assays concerning cancer treatment, a two-stage evaluation is contemplated in which both acute cytotoxic and longer term inhibitory effect of a given anti-cancer agent are investigated.Type: GrantFiled: March 8, 2005Date of Patent: September 26, 2006Assignee: Precision Therapeutics, Inc.Inventor: Paul L. Kornblith
-
Patent number: 6933129Abstract: An improved system for screening a multiple of candidate therapeutic or chemotherapeutic agents for efficacy as to a specific patient, in which a tissue sample from the patient is harvested, cultured and separately exposed to a plurality of treatments and/or therapeutic agents for the purpose of objectively identifying. One particularly important tissue sample preparation technique is the initial preparation of cohesive multicellular particulates of the tissue sample. For assays concerning cancer treatment, a two-stage evaluation is contemplated in which both acute cytotoxic and longer term inhibitory effect of a given anti-cancer agent are investigated.Type: GrantFiled: March 16, 1998Date of Patent: August 23, 2005Assignee: Precision Therapeutics, Inc.Inventor: Paul L. Kornblith
-
Patent number: 6900027Abstract: An improved system for screening a multiple of candidate therapeutic or chemotherapeutic agents for efficacy as to a specific patient, in which a tissue sample from the patient is harvested, cultured and separately exposed to a plurality of treatments and/or therapeutic agents for the purpose of objectively identifying the best treatment or agent for the particular patient. The system includes the initial preparation of cohesive multicellular particulates of the tissue sample, rather than enzymatically dissociated cell suspensions or preparations, for initial tissue culture monolayer preparation. Practical monolayers of cells may thus be formed to enable meaningful screening of a plurality of treatments and/or agents. By subjecting uniform samples of cells to a wide variety of active agents (and concentrations thereof), the most promising agent and concentration for treatment of a particular patient can be determined.Type: GrantFiled: March 17, 1998Date of Patent: May 31, 2005Assignee: Precision Therapeutics, Inc.Inventor: Paul L. Kornblith
-
Patent number: 6887680Abstract: An improved system for screening a multiple of candidate therapeutic or chemotherapeutic agents for efficacy as to a specific patient, in which a tissue sample from the patient is harvested, cultured and separately exposed to a plurality of treatments and/or therapeutic agents for the purpose of objectively identifying the best treatment or agent for the particular patient. Specific method innovations such as tissue sample preparation techniques render this method practically as well as theoretically useful. One particularly important tissue sample preparation technique is the initial preparation of cohesive multicellular particulates of the tissue sample, rather than enzymatically dissociated cell suspensions or preparations, for initial tissue culture monolayer preparation.Type: GrantFiled: July 26, 2002Date of Patent: May 3, 2005Assignee: Precision Therapeutics, Inc.Inventor: Paul L. Kornblith
-
Publication number: 20040023375Abstract: An improved method for preparing a cell culture is disclosed. The method includes culturing a multicellular tissue explant in the presence of growth medium that is substantially free of enzymes capable of digesting the explant and, subsequently, removing the explant at a predetermined time.Type: ApplicationFiled: July 30, 2002Publication date: February 5, 2004Applicant: Precision Therapeutics, Inc.Inventors: Paul L. Kornblith, Sheri Gimigliano
-
Publication number: 20020192638Abstract: An improved system for screening a multiple of candidate therapeutic or chemotherapeutic agents for efficacy as to a specific patient, in which a tissue sample from the patient is harvested, cultured and separately exposed to a plurality of treatments and/or therapeutic agents for the purpose of objectively identifying the best treatment or agent for the particular patient. Specific method innovations such as tissue sample preparation techniques render this method practically as well as theoretically useful. One particularly important tissue sample preparation technique is the initial preparation of cohesive multicellular particulates of the tissue sample, rather than enzymatically dissociated cell suspensions or preparations, for initial tissue culture monolayer preparation.Type: ApplicationFiled: July 26, 2002Publication date: December 19, 2002Applicant: Precision Therapeutics, Inc.Inventor: Paul L. Kornblith
-
Patent number: 6416967Abstract: A comprehensive and integrated system for monitoring (identifying, tracking and analyzing) an individual patient's malignancy or hyperproliferative syndrome through the duration of a malignancy or hyperproliferative syndrome as to a specific patient is provided. Specimens of a patient's cells are collected and mechanically separated into cohesive multicellular particulates. A tissue culture monolayer is grown from the multicellular particulates to form a prime culture, and the tissue culture is monitored over a period of time. The invention allows for study of the effect of various treatment methods on cellular production of vascular endothelial growth factor.Type: GrantFiled: November 10, 1998Date of Patent: July 9, 2002Assignee: Precision Therapeutics, Inc.Inventor: Paul L. Kornblith
-
Patent number: 5728541Abstract: An improved system for screening a multiple of candidate therapeutic or chemotherapeutic agents for efficacy as to a specific patient, in which a tissue sample from the patient is harvested, cultured and separately exposed to a plurality of treatments and/or therapeutic agents for the purpose of objectively identifying the best treatment or agent for the particular patient. The system includes the initial preparation of cohesive multicellular particulates of the tissue sample, rather than enzymatically dissociated cell suspensions or preparations, for initial tissue culture monolayer preparation. Practical monolayers of cells may thus be formed to enable meaningful screening of a plurality of treatments and/or agents. By subjecting uniform samples of cells to a wide variety of active agents (and concentrations thereof), the most promising agent and concentration for treatment of a particular patient can be determined.Type: GrantFiled: July 12, 1996Date of Patent: March 17, 1998Assignee: Precision Therapeutics, Inc.Inventor: Paul L. Kornblith